Valuation: biote Corp.

Market Cap 31.12M 27.66M 25.64M 23.32M 44.01M 2.95B 44.72M 308M 121M 1.54B 117M 114M 4.91B P/E 2026 *
-5.29x
P/E 2027 * 6.38x
Enterprise Value 31.12M 27.66M 25.64M 23.32M 44.01M 2.95B 44.72M 308M 121M 1.54B 117M 114M 4.91B EV / Sales 2026 *
0.17x
EV / Sales 2027 * 0.17x
Free-Float
77.11%
Yield 2026 *
-
Yield 2027 * -
1 day-2.25%
1 week-5.65%
Current month-10.33%
1 month-19.63%
3 months-55.35%
6 months-51.13%
Current year-58.27%
1 week 1
Extreme 1
1.21
1 month 1
Extreme 1
1.4
Current year 1
Extreme 1
2.68
1 year 1
Extreme 1
3.26
3 years 1
Extreme 1
8.44
5 years 1
Extreme 1
10.52
10 years 1
Extreme 1
10.52
Manager TitleAgeSince
Chief Executive Officer 49 12/06/2026
Chief Tech/Sci/R&D Officer 69 01/03/2024
General Counsel - -
Director TitleAgeSince
Chairman 61 01/05/2022
Director/Board Member 51 01/05/2022
Director/Board Member 63 01/05/2022
Date Insider Type Main position Quantity % Market Cap. Importance
11/08/26 Buy

Chairman

16,000 0.0528%
12/05/26 Free

Director

161,481 0.5039%
12/05/26 Exercice

Director

211,850 0.6611%
Change 5-day change 1-year change 3-year change Capi.($)
-2.25%-5.65%-61.80%-79.83% 31.12M
+1.14%+5.35%-9.20%+16.97% 127B
+0.29%+4.49%+2.98%+50.92% 84B
+0.67%+4.65%-31.69%-12.01% 47.21B
-1.05%+0.70%+6.50%+10.33% 41.37B
-0.60%+5.82%-18.38%+3.54% 33.18B
+0.12%+8.69%-25.31%-32.60% 20.44B
+0.57%+5.84%-23.53%-3.31% 19.77B
-0.01%+10.61%-28.94%-10.84% 18.94B
+1.30%+3.89%+13.35%+60.60% 16.88B
Average +0.02%+4.39%-17.60%+0.38% 40.85B
Weighted average by Cap. +0.42%+5.01%-9.94%+15.88%

Financials

2026 *2027 *
Net sales 178M 158M 147M 133M 252M 16.89B 256M 1.76B 691M 8.81B 668M 654M 28.09B 188M 167M 155M 141M 265M 17.81B 270M 1.86B 728M 9.29B 704M 689M 29.62B
Net income -5.99M -5.33M -4.94M -4.49M -8.48M -569M -8.61M -59.35M -23.27M -297M -22.49M -22.01M -946M 3.76M 3.35M 3.1M 2.82M 5.33M 357M 5.41M 37.29M 14.62M 186M 14.13M 13.83M 594M
Net Debt - -
Projected Income Statement - Annual - biote Corp.
Logo biote Corp.
biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
Employees
223
Date Price Change Volume
16/10/26 $1.085 -2.25% 41,588
15/10/26 $1.110 -1.77% 43,243
14/10/26 $1.130 +8.65% 144,785
13/10/26 $1.040 -8.77% 387,353
12/10/26 $1.140 -0.87% 63,334
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - biote Corp.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.085USD
Average target price
2.612USD
Spread / Average Target
+140.74%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - biote Corp.
  1. Stock Market
  2. Stocks
  3. BTMD Stock